1. TP53mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
- Author
-
Jeremy Chien, R. Keira Cheetham, Yan W. Asmann, Ellen L. Goode, Jean Pierre A. Kocher, Lynn C. Hartmann, Scott H. Kaufmann, Russell J. Grocock, Julie M. Cunningham, Yaman Tarabishy, Steven N. Hart, John F. Peden, Ann L. Oberg, Ying Li, Kimberly R. Kalli, Rui Kuang, Marina Bibikova, David Bentley, Jaime I. Davila, Elizabeth J. Atkinson, Saurabh Baheti, Sabine Dietmann, Viji Shridhar, Chen Wang, Debra A. Bell, Takayo Ota, Elizabeth M. Swisher, Jian-Bing Fan, Hugues Sicotte, and Sean Humphray
- Subjects
p53 ,Mutation rate ,endocrine system diseases ,Somatic cell ,Loss of Heterozygosity ,DNA Primase ,Biology ,Loss of heterozygosity ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Mutation Rate ,Information and Computing Sciences ,Genetics ,Carcinoma ,medicine ,Humans ,2.1 Biological and endogenous factors ,neoplasms ,Cancer ,030304 developmental biology ,Ovarian Neoplasms ,0303 health sciences ,Prevention ,Human Genome ,Recombinational DNA Repair ,Genomics ,Biological Sciences ,Genes, p53 ,medicine.disease ,BRCA2 Protein ,Molecular biology ,Ovarian Cancer ,3. Good health ,Tetraploidy ,Genes ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,Female ,Ploidy ,Homologous recombination ,Ovarian cancer ,Environmental Sciences ,Biotechnology ,Developmental Biology - Abstract
To determine early somatic changes in high-grade serous ovarian cancer (HGSOC), we performed whole genome sequencing on a rare collection of 16 low stage HGSOCs. The majority showed extensive structural alterations (one had an ultramutated profile), exhibited high levels of p53 immunoreactivity, and harboured a TP53 mutation, deletion or inactivation. BRCA1 and BRCA2 mutations were observed in two tumors, with nine showing evidence of a homologous recombination (HR) defect. Combined Analysis with The Cancer Genome Atlas (TCGA) indicated that low and late stage HGSOCs have similar mutation and copy number profiles. We also found evidence that deleterious TP53 mutations are the earliest events, followed by deletions or loss of heterozygosity (LOH) of chromosomes carrying TP53, BRCA1 or BRCA2. Inactivation of HR appears to be an early event, as 62.5% of tumours showed a LOH pattern suggestive of HR defects. Three tumours with the highest ploidy had little genome-wide LOH, yet one of these had a homozygous somatic frame-shift BRCA2 mutation, suggesting that some carcinomas begin as tetraploid then descend into diploidy accompanied by genome-wide LOH. Lastly, we found evidence that structural variants (SV) cluster in HGSOC, but are absent in one ultramutated tumor, providing insights into the pathogenesis of low stage HGSOC.
- Published
- 2015
- Full Text
- View/download PDF